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Introduction
Glioblastoma multiforme (GBM) is the most common 
and malignant type of brain tumor that has a mean 
patient survival of about 14 months despite the surgery, 
chemotherapy, and radiotherapy. Routine therapeutic 
procedures, including invasive surgery, chemotherapy, 
and radiation therapy, are still unsuccessful. GBM is 
highly metastatic, and like most other nervous tissue 
tumors is not sensitive to chemotherapy.1 Other factors, 
such as the disruption of the blood-brain barrier, the 
loss of well-defined boundary between tumor cells 
and healthy nervous tissues, and intolerance of healthy 
cells against radiation, lead to the failure of standard 
therapeutic methods.2 Surgery, chemotherapy, and 
radiotherapy are not still able to increase the rate of 
patient survival. Therefore, the treatment of central 
nervous system (CNS) tumors aims to establish good 
living conditions by reducing each therapy’s neurological 
side effects. However, disappointing results have led to 
the use of new and combined therapies in clinical and 
experimental research. Botulinum toxin type A (BtxA) 
is a protein produced by bacterium Clostridium. BtxA is 
lethal but now consider as an active treatment agent. BtxA 
is used to treat muscular spasm, facial paralysis, chronic 
lumbar pain, specific symptoms of stroke, brain damage, 
and neuromuscular disorders.3 Rajkumar et al in 2005 
reported the clinical efficacy of intravesical injection of 
BtxA on detrusor muscle of urinary bladder in patients 
with urinary bladder dysfunction.4 They showed that 
BtxA decreased signs and symptoms of the disease 
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Abstract
Background: Glioblastoma multiforme (GBM) is the most type of brain malignancy in adults. 
Radical excision surgery, chemotherapy, and radiotherapy in some cases are still unsuccessful, and 
most patients with GBM die within 3 to 6 months following diagnosis. Botulinum toxin type A (BtxA) 
has cellular toxin effects and suppresses the cell division of certain types of cancer cell lines in vivo 
and in vitro study. The present study designed to evaluate the apoptotic effect of BtxA on the GBM 
cell line. 
Methods: U87-MG GBM cell line cultured according to the routing protocols, divided into 2 groups 
including, trial (BtxA treated) and control groups. Cells of the trial group exposed to different doses 
of BtxA. The cell viability, cycle arrest, and pro-apoptotic proteins evaluated respectively by MTT 
assay, subG1, and Western blotting. 
Results: MTT assay showed that the viability of the BtxA treated cells at doses of 1.45 Unit and 
other doses after 24 to 48 hours, significantly decreased (P < 0.001) compared to the control groups. 
Apoptosis percentage of the subG1 test also indicated that 1.45 unit dose significantly increased in 
the cells exposed to BtxA compared to the control group in 24 hours. The expression of P53 and 
caspase 3 proteins indicated a significant increase. 
Conclusion: BtxA induces apoptosis in U87-MG cell line via p53 and caspase 3 pathways and could 
have clinical applications. In vivo studies need to confirm the clinical application of the present 
findings. 
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without any adverse effects.4 Darwish et al in 2014 showed 
that BtxA might lead to undesirable histopathological 
effects in testicular tissue of adult rats treated with BtxA 
that might lead to infertility.5 There are also other studies 
indicating that BtxA is a safe and effective treatment in a 
dose-dependent manner.6,7 Many studies focus on the in 
vitro investigation of BtxA.
Karsenty et al, in 2009, showed induction of apoptosis 
of the human prostate cancer LNCaP and PC-3 cell lines 
by BtxA in a dose-dependent manner.8 In 2013 Bandala 
et al conducted a study to evaluate the apoptotic effect 
of BtxA on T47D breast cancer cells. According to their 
results, BtxA caused significant cytotoxic and apoptotic 
effects on T47D cells.9 How BtxA induces apoptosis is 
still unknown. However, it seems that BtxA may act 
throughout the intrinsic pathway of apoptosis involving 
p53 and caspase 3 proteins. The p53 protein involves 
stopping cell cycles and the onset of apoptosis in response 
to DNA damage. It also stimulates the transcription of 
several genes that stop cell cycles and initiates apoptosis. 
The cessation of the cell cycle occurs by p53 at the end 
of the G1 stage and has generated by a transcriptional 
p53-dependent inhibitor of CDK (cyclin-dependent 
kinase), i.e., p21.10 Caspases are family proteins that are 
crucial mediators of apoptosis. Among them, caspase 3 
is a frequently activated death protease, catalyzing the 
specific cleavage of many vital cellular proteins. Caspase 3 
is essential for healthy brain development and is essential 
for apoptotic scenarios in remarkable tissue. Caspase-3 
is also required for some typical hallmarks of apoptosis 
and is essential for apoptotic chromatin condensation and 
DNA fragmentation. To our knowledge, there is a lack of 
enough evidence for the effects of BtxA on the GBM cell 
line. Thus, regarding the anti-proliferative and apoptotic 
role of BtxA, the present research designed in order to 
study the apoptotic effects of BtxA on the GBM cell line 




DMEM, FBS (Gibco), and DMSO purchased from Sigma 
Aldrich. Botox (Canitox as the most common brand in 
Iran), p53 (1C12) and caspase 3 (9662s) Mouse mAb 
were purchased from Cell Signaling Technology Inc. 
Propidium iodide was purchased from Abcam.
Cell Culture
The U87MG glioblastoma cell line has purchased from 
the Tehran Pasteur Institute. Cells cultured in DMEM 
medium containing 10% FBS with a cell density of 104 
cells/cm2, and was then placed in incubators with 5% of 
CO2 and 98% of humidity at 37°C and stored up to 10 
passages.
Microscopic Evaluated
The cells before and after treatment have evaluated by 
invert microscopy.
Viability assay
Two groups of cells, including treated cells with different 
concentrations of BtxA and control with an approximate 
cell number of 1×104 cultured in 96-well plates studied in 
this test. The 96-well plate was moved into the incubator 
for 24 hours, following adhesion of cells, BtxA treatment 
for 24 and 48 hours with different doses of 0.75, 0.85, 0.95, 
1.05, 1.15, 1.25.1.35, 1.45, 1.65, 1.85, 2.05 units has done. 
All treatment steps performed on ice and MTT solution 
was added to each well incubated at 37°C for 2-4 hours. 
The obtained optical absorption read by EllSA reader at 
570 nm.
SubG1 Assay
The control and BtxA treated cells observed for the cell 
cycle analysis. In this method, cells were evaluated after 
fixation and staining with PI through the flow cytometry. 
PI color is capable of binding to DNA and RNA in fixed 
cells, and thus RNase is used for stain cells so that only 
the DNA content of cells could detect and measured the 
loss of RNA.
For subG1 assay, the cells were cultured in a 12-well 
plate and divided into 2 groups of control, and BtxA 
treated cells. Trail cells exposed to the 1.45U and 1.65U 
doses of BtxA for 24 and 48 hours. Supernatant removed, 
and cells washed with PBS and 70% alcohol. Cells have 
kept at -20˚C for 24 hours. RNase and PI added at a 
concentration of 1 mg/mL, incubated for 30 minutes at 
ambient temperature in a dark place; they were read by 
flow cytometry after 30 minutes.
Western Blotting for Caspase 3 and p53 Proteins 
The protein was extracted from the cell and placed on 
the SDS-PAGE gel. The SDS PAGE gel used to purify 
proteins of U87MG cells. Thirty micrograms protein 
was separated on the gel-protein samples and transferred 
to the polyvinylidene difluoride (PVDF) membrane, 
and eventually, protein samples, which revealed on the 
PVDF membrane, were detected using the ECL kit. After 
blocking with buffer containing 3% of ECL Advance in 
PBS/Tween 0.3% for 1.5 hours at room temperature, the 
membrane probed with specific polyclonal antibodies 
(Abcam) diluted in blocking solution (Caspase3 1:7500, 
P53 1:7500) antibodies were added to the membrane 1 
hour at room temperature. Then, a secondary antibody 
added onto the membrane. After the incubation time, the 
secondary antibodies were removed and washed by a tris-
buffered saline (TBS) buffer for 3 to 10 minutes.
Statistics 
All experiments were repeated at least 3 times. The data 
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were presented as means ± standard deviation (SD). The 
statistical analysis was performed using Kolmogorov-
Smirnov to check the normal distribution of data; and 
Tukey test to check the equality of variances. The one-way 
ANOVA was used for comparison.
Results
Microscopic study showed the BtxA treated cells were 
detached and changed in shape, granulation compared to 
the cells of the control group. These features showed early 
signs of apoptosis in BtxA treated cells (Figure 1). 
Viability test showed a significant difference between 
the percentage of live cells in the control group compared 
to BtxA treated cells at doses of 1.45, 1.65, 1.85 and 2.05 
units (P < 0.001) after 24 and 48 hours in a dose-dependent 
manner. There was a non-significant difference between 
24 and 48 hours BtxA treated groups, the number of live 
cells in BtxA treated within 24 hours was less than the live 
cells within 48 hours of treating (Figure 2). 
For the subG1 assay, the BtxA treated cells at doses 
of 1.45 and 1.65 units within 24 hours, which showed 
meaningful results in MTT assay, were used. 
Treating with doses of 1.45 and 1.65 Units within 24 
hours showed 56.58% and 83.63% of dead cells compared 
to the control group, respectively (Figure 3).
Figure 4 shows the comparison of apoptosis between 
Figure 1. Micrograph of control cells group (A) and U87-MG 
cells BtxA treated groups (B) after 24 hours (×100).
Figure 2. MTT assay: The Percentages of Live Cells in Control 
and BtxA Treated Groups After 24h and 48h. 
Mean±SD, *P < 0.001 48hr compared to the control at the same 
time. # P < 0.001 48 hr compare to 24hr.
Figure 3. SubG1 Assay of Botox Treatment and Control Groups 
at 1.45 and 1.65 Unit Dose After 24 Hours. 
24 and 48 hours of BtxA treatment at a dose of 1.45. 
Accordingly, there was a significant difference between 
the number of apoptotic cells in the BtxA treated group 
at 1.45 Units within 24 hours compared to the same dose 
within 48 hours of BtxA treating (P < 0.05). 
Western blotting results showed a significant increase 
in caspase 3 and p53 in BtxA treated group at the dose of 
1.45 units within 24 hours compared to the control group 
(P < 0.001). 
Discussion 
Radical invasive surgery following by radiation and 
chemotherapy still is the first clinical decision to treat 
patients with GBM.11 Although this type of treatment is 
used frequently for most cases of cancers, unfortunately, 
there is the loss of enough success since most brain tumors 
are recurrent and not sensitive effectively to currently 
chemicals agents.12 Due to difficulties in surgery of 
anatomical position of the tumors, not enough sensitivity 
of tumor cells to chemotherapy and radiation therapy, 
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recently, researchers are thinking of adjuvant therapies.13 
Since the Food and Drug Administration (FDA) approved 
the BtxA, it has widely applied in clinical practice. BtxA is 
known to act at nerve endings by blocking the exocytosis 
of various neurotransmitters through the endopeptidase 
activity of its light chain that cleaves SNAP-25. A protein 
belonging to the SNARE (soluble N-ethyl maleimide-
sensitive factor attachment protein receptor) complex 
known to regulate the fusion of presynaptic vesicles to 
the plasma membrane.8 As our data showed, BtxA has 
the potential to induce apoptosis in U87-GM GBM cell 
line in the dose and time-dependent manner. Some other 
similar researches are using BtxA for the treatment of a 
certain type of tumor cells. Treating T47D breast cancer 
cell line and MCF10A normal cell line by BtxA reported 
by Bandala et al in 2013. They showed that BtxA has 
cytotoxic effects on these cells; their results showed that 
the effectiveness of BtxA on T47D cells is more than the 
effects of BtxA treating of MCF10A. The dosing unit 
that they used for BtxA was 5.3 units within 24 hours of 
exposure time. They also claimed that the BtxA induces 
apoptosis via activation of caspases 3 and 7.9 Their results 
are close to our findings on the GBM cell line with 
some differences. Despite the similarity in exposing and 
effective time of BtxA, the effective dose of our research 
(1.45 unit) was different from their dose (5.3 unit) that 
might be due to the sensitivity of the cell lines. Our data 
confirmed the role of caspase 3 in apoptosis induction. 
In another study, Karsenty et al showed the effectiveness 
of BtxA on the human LNCaP prostate cancer cell 
line. They showed that the BtxA induces apoptosis and 
prevents the growth of prostate cancer cells in vitro and 
in vivo.9 They showed the role of synaptic vesicles (SV) 
proteins such as SV2 membrane receptor for the act of 
BtxA on LNCap cell line and hypothesized that the 
presence of SV2 in LNCaP might allow the BtxA light 
chain to enter the cells and, block exocytosis of paracrine 
or autocrine factors involved in cell proliferation. There 
are some controversies regarding the apoptotic effect 
of BtxA. Although some researchers have pointed to 
the apoptosis induction role of BtxA, other researchers 
have shown that BtxA could protect against apoptosis. 
Shi et al, in 2019, showed the antiapoptotic effects of 
BtxA on human dermal microvascular endothelial 
cells. According to them, BtxA prevents cytochrome C 
release and by decreasing the expression of caspase 3, 
inhibits apoptosis.13 Their results are in contrast with 
the findings of this study, and we guess the type of the 
cell line might consider as the factor that influences the 
results, or it is also possible that the BtxA goes by different 
pathways in various cells to inhibit or induce apoptosis. 
We also showed an increase in the expression of p53 
and caspase 3 in BtxA treated cells. The p53 gene is the 
most-widely known tumor suppressor gene and plays 
a major role in inducing apoptosis14 also, caspase-3 is 
essential for apoptotic chromatin condensation and DNA 
fragmentation. Regarding Karsenty et al explanation, we 
hypothesized that there might be some mechanisms for 
the effect of BtxA on the U87-GM cell line. We think that 
the activation of the p53 and caspase 3 might be due to the 
BtxA effect on membrane receptors of the GBM cell line. 
Figure 4. The Percentage of Apoptotic Cells by SubG1 Assay. 
mean±SD, *P < 0.05, **P < 0.001 significant differences 
compared to control. &P < 0.05 significant differences Compared 
between groups P < 0.05
Figure 5. The Expression of Caspase 3 & P53 Protein by Western Blotting Between the Control and 1.45 BtxA group. 
Mean ± SD, *P < 0.05, **P < 0.001. 
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Zhang et al mentioned the details of the p53 pathway in 
GBM. They emphasized the deregulation of the p53-ARF-
MDM2 pathway at 84% of GBM patients and 94% of the 
GBM cell line. According to their results, the deregulated 
p53 pathway component has implicated in GBM cell line 
invasion, migration, proliferation, initiation of apoptosis, 
and cancer cells.14 Analysis and the clinical importance 
of the expression of receptors in different grade (I-IV) 
of GBM reported by Hu et al.15 The expression of the SV 
proteins family of GBM reported by de Groot et al.16 They 
showed the expression of SV2 in GBM of grade II patients. 
They also claimed that the expression of SV2 might show 
a better prognosis for these patients. From a clinical point 
of view about p53, Jin et al in 2016 reported the prognostic 
importance of p53 in patients with GBM. They concluded 
that p53 immunohistochemical expression might have 
effective usefulness in predicting the prognosis in patients 
with glioma.17 So BtxA and other adjuvant therapy with 
the capability of increasing the p53 expression could be 
useful to the treatment of this type of malignancy. 
Regarding the expression of caspase 3, we showed that 
BtxA increased the level of its expression significantly 
in the GBM cell line. Tirapelli et al in 2010 reported the 
low expression of caspase 3 in samples of patients with 
GBM that in turn shows the resistance of GBM cell to 
apoptosis.18 So any treatment increased the expression 
of caspase 3 might be clinically useful. In addition to 
the novelty of treating GBM cell line by BtxA that first 
reported, we also showed the expression of p53 and 
caspase 3 with more focus on p53, which is very close to 
recent findings role of the p53 pathway in treatment and 
prognosis of patients with GBM. 
Conclusion
We reported the first observation of growth inhibition 
and apoptosis in the U87-GM GBM cell line by BtxA in 
vitro. Based on our findings, BtxA has the potential to 
suppress U87-MG GBM cells and inducing apoptosis via 
activation of the intrinsic apoptotic pathway. BtxA might 
use clinically for human GBM tumors. However, it needs 
further investigations. Whether BtxA could use along 
with other routine therapeutic procedures for patients 
with GBM is also a matter of research and question.
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